COVID-19 : Oxford University vaccine shows 70% protection, Being Made In India With Serum Institute

AstraZeneca chief executive Pascal Soriot said that this vaccine’s effectiveness and security prove that it will be highly useful against COVID-19 and will have a direct impact on this public health emergency.

AstraZeneca also said this vaccine for the novel coronavirus could be around 90% efficient without any severe side effects, the most advanced drugmaker to reveal positive interim data in a scientific race to curb a global pandemic.

The vaccine produced by Oxford University was 90% effective in inhibiting COVID-19 when it was implemented as a half dose followed by a full dose at least one month apart, according to the late-stage tests in Brazil and Britain.

No severe safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens.

The Serum Institute of India, the world’s greatest manufacturer of vaccines, has partnered with AstraZeneca, the Gates Foundation, and the Gavi vaccine alliance to contribute more than a billion doses of a novel coronavirus vaccine for global supply.

The British drugmaker’s introductory trial events mark a fresh invention in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.

Different dosing regimens conferred 63% vigor when given as 2 full doses at least one month, and the joined study from both dosing regimens resulted in an average efficacy of 70%. All results were statistically important. The interim report was based on 132 infections among members who received the vaccine and those in a control group who were given an established meningitis shot.

AstraZeneca is now developing supervisory submissions of the data to officials around the world that have a framework in place for limited or early approval.

The Company will attempt an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. In parallel, the full report of the interim results is being submitted for publication in a peer-reviewed journal, the company announcement read.